# US 2021/0332083 A1 · Netrin-1 Compounds and Compositions Thereof for Treating Pulmonary Hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332083 A1
- Document ID: US20210332083A1
- Status: Published application
- Kind: A1
- Application number: 17/286,857
- Filed: 2019-12-11
- Published: 2021-10-28
- Earliest claimed: 2018-12-12
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Hua Cai
- Web page: https://patentgrep.com/patent/US20210332083A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 9/12: Antihypertensives
- C07K 14/475: Growth factors; Growth regulators
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are netrin-1 compounds and compositions thereof and methods of using thereof to treat pulmonary hypertension. In some embodiments, the present invention provides methods of treating, reducing, or inhibiting pulmonary hypertension or reducing a subjects mean pulmonary arterial pressure (mPAP) and/or the subjects right ventricular systolic pressure (RVSP), which methods comprise administering to the subject a therapeutically effective amount of one or more netrin-1 compounds.

## Claims

### Claim 1

A peptide comprising, consisting essentially of, or consisting of SEQ ID NO: 1 as follows:
X1-X2-X3-C-X4-X5-X6-X7-T-X8-G (SEQ ID NO: 1)
wherein
X1 is Ala, Asn, Cys, D-Cys, Ser, or Thr, preferably X1 is Cys, Ser, or Thr, wherein when X1 is Cys, it is linked, e.g., attached covalently or non-covalently to either the cysteine residue at the fourth amino acid position via a disulfide bond or an ethylene oxide compound;
X2 is present or absent, and if present, X2 is Ala, Asp, Ile, Leu, Met, Phe, Pro, Trp, or Val, preferably X2 is Leu or Pro;
X3 is present or absent, and if present, X3 is Asn, Arg, Asp, Cys, Gln, Glu, Gly, Ser, Thr, or Tyr, preferably X3 is Asn or Asp;
X4 is Arg, His, or Lys, preferably X4 is Arg or Lys;
X5 is Arg, Asp, Glu, His, Lys, Phe, Trp, or Tyr, preferably X5 is Asn, Asp, or His;
X6 is Asn, Cys, Gln, Gly, Ser, Thr, Tyr, or Val, preferably X6 is Asn or Gly;
X7 is present or absent, and if present, X7 is Asn, Gly, His, Ile, Thr, or Val, preferably X7 is Val; and
X8 is present or absent, and if present, X8 is Ala, Asn, Ile, Leu, Met, Phe, Pro, Thr, Trp, or Val, preferably X8 is Ala; and
wherein X2, X3, or both X2 and X3 are present, and when X1 is D-Cys, preferably the last amino acid residue at the C-terminal end is a D-amino acid, or both the glycine residue at the 10th amino acid position and the last amino acid residue at the C-terminal end are D-amino acids.

### Claim 2 (depends on 1)

The peptide according to claim 1, wherein the ethylene oxide compound is polyethylene glycol (PEG), polyethylene oxide (PEO), and polyoxyethylene (POE), methoxypolyethylene glycol (MPEG), or monomethoxypolyethylene glycol (mPEG), or diethylene glycol (mini-PEG), preferably the ethylene oxide compound is mini-PEG.

### Claim 3 (depends on 1)

The peptide according to claim 1, wherein the peptide comprises, consists essentially of, or consists of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8.

### Claim 4 (depends on 1)

The peptide according to claim 1, wherein the peptide is about 8-60, about 8-55, about 8-50, about 8-45, about 8-40, about 8-35, about 8-30, about 8-25, about 8-20, about 8-15, about 8-12, 8-11, about 9-60, about 9-55, about 9-50, about 9-45, about 9-40, about 9-35, about 9-30, about 9-25, about 9-20, about 9-15, about 9-12, or 9-11 amino acid residues long.

### Claim 5 (depends on 1)

The peptide according to claim 1, wherein the peptide is 8, 9, 10, or 11 amino acid residues long.

### Claim 6 (depends on 1)

A composition comprising one or more peptides according to claim 1.

### Claim 7 (depends on 13)

A method of treating, reducing, or inhibiting pulmonary hypertension in a subject, which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the pulmonary hypertension is pulmonary artery hypertension (PAH), due to left heart disease, due to lung disease, due to hypoxia or chronic hypoxia (such as secondary to COPD and interstitial lung disease), due to blood clots in the lungs, or due to a blood disorder or other disease.

### Claim 9 (depends on 13)

A method of reducing a subject's mean pulmonary arterial pressure (mPAP) and/or the subject's right ventricular systolic pressure (RVSP), which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.

### Claim 10 (depends on 13)

A method of treating, reducing, or inhibiting right ventricular hypertrophy, medial wall thickening, and/or muscularization and cell proliferation in a subject, which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the right ventricular hypertrophy, medial wall thickening, and muscularization and cell proliferation is caused by hypoxia and/or pulmonary hypertension.

### Claim 12 (depends on 13)

A method of preserving or maintaining nitric oxide (NO) bioavailability while attenuating, reducing, or inhibiting reactive oxygen species (ROS) production caused by hypoxia and/or pulmonary hypertension in a subject, which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.

### Claim 13

A netrin-1 compound which is a peptide that has an amino acid sequence that comprises, consists essentially of, or consists of SEQ ID NO: 1 as follows:
X1-X2-X3-C-X4-X5-X6-X7-T-X8-G (SEQ ID NO: 1)
wherein
X1 is Ala, Asn, Cys, D-Cys, Ser, or Thr, preferably X1 is Cys, D-Cys, Ser, or Thr;
X2 is present or absent, and if present, X2 is Ala, Asp, Ile, Leu, Met, Phe, Pro, Trp, or Val, preferably X2 is Leu or Pro;
X3 is present or absent, and if present, X3 is Asn, Arg, Asp, Cys, Gln, Glu, Gly, Ser, Thr, or Tyr, preferably X3 is Asn or Asp;
X4 is Arg, His, or Lys, preferably X4 is Arg or Lys;
X5 is Arg, Asp, Glu, His, Lys, Phe, Trp, or Tyr, preferably X5 is Asn, Asp, or His;
X6 is Asn, Cys, Gln, Gly, Ser, Thr, Tyr, or Val, preferably X6 is Asn or Gly;
X7 is present or absent, and if present, X7 is Asn, Gly, His, Ile, Thr, or Val, preferably X7 is Val; and
X8 is present or absent, and if present, X8 is Ala, Asn, Ile, Leu, Met, Phe, Pro, Thr, Trp, or Val, preferably X8 is Ala; and
wherein X2, X3, or both X2 and X3 are present.

### Claim 14 (depends on 13)

The netrin-1 compound according to claim 13, wherein X1 is D-Cys and the last amino acid residue at the C-terminal end is a D-amino acid, or both the glycine residue at the 10th amino acid position and the last amino acid residue at the C-terminal end are D-amino acids.

### Claim 15 (depends on 13)

The netrin-1 compound according to claim 13, wherein X1 is Cys, which is attached to either the cysteine residue at the fourth amino acid position of SEQ ID NO: 1 via a disulfide bond or an ethylene oxide compound.

### Claim 16 (depends on 7)

The method according to claim 7, wherein the netrin-1 compound is a peptide that comprises, consists essentially of, or consists of an amino acid sequence that has at least 90% sequence identity to SEQ ID NO: 9.

### Claim 17 (depends on 7)

The method according to claim 7, wherein the netrin-1 compound is a peptide having an amino acid sequence that comprises, consists essentially of, or consists of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17.

### Claim 18 (depends on 7)

The method according to claim 7, wherein the netrin-1 compound is about 8-60, about 8-55, about 8-50, about 8-45, about 8-40, about 8-35, about 8-30, about 8-25, about 8-20, about 8-15, about 8-12, 8-11, about 9-60, about 9-55, about 9-50, about 9-45, about 9-40, about 9-35, about 9-30, about 9-25, about 9-20, about 9-15, about 9-12, or 9-11 amino acid residues long, preferably the netrin-1 compound is 8, 9, 10, or 11 amino acid residues long.

### Claim 19 (depends on 7)

The method according to claim 7, wherein the one or more netrin-1 compounds are administered in the form of a pharmaceutical composition.
